DRUG
Linaclotide 290 micrograms
Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
Status
Completed
Phase
Phase 3
Enrollment
803
Locations
118
Results
Posted
Publications
2
Study summary
The objective of this trial is to determine the efficacy and safety of linaclotide administered to patients with irritable bowel syndrome with constipation (IBS-C). The primary efficacy parameter is the percentage of patients in each treatment group that meet the protocol definition for Abdominal Pain and Complete Spontaneous Bowel Movement (APC) Responder.
Interventions
DRUG
Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
DRUG
Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
Timeline
First posted
Jul 29, 2009
Study start
Jul 2009
Primary completion
Jul 2010
Study completion
Aug 2010
Results posted
Jan 30, 2013
Registry updated
Jan 30, 2013
Outcomes
Abdominal Pain and Complete Spontaneous Bowel Movement (APC) Responder, 9 Out of 12 Weeks
Time frame · Change from Baseline to Week 12
A patient is considered to be an APC responder if, for at least 9 out of the 12 weeks of the treatment period, the patient had at least 3 CSBMs, experienced an increase of at least 1 CSBM from baseline, and experienced a decrease of at least 30 percent in their Abdominal Pain (AP) score from baseline during a particular week. The AP score assesses the worst of a patient's AP in the past 24 hours using an 11-point scale (from 0-10), where 0 represents no AP and 10 represents very severe AP. A CSBM is defined as a spontaneous bowel movement, associated with a sense of complete evacuation.
Complete Spontaneous Bowel Movement (CSBM) 3+1 Responder, 9 Out of 12 Weeks
Time frame · Change from Baseline to Week 12
A patient is considered to be a CSBM 3+1 responder if, for at least 9 out of the 12 weeks of the treatment period, the patient had at least 3 CSBMs and experienced an increase of at least 1 CSBM from baseline during a particular week. A CSBM was defined as a Spontaneous Bowel Movement (SBM) that was associated with a sense of complete evacuation. An SBM was defined as a bowel movement (BM) that occurred in the absence of laxative, enema, or suppository use on either the calendar day of the BM or the calendar day before the BM.
Abdominal Pain Responder, 9 Out of 12 Weeks
Time frame · Change from Baseline to Week 12
A patient is considered to be an abdominal pain responder if, for at least 9 out of the 12 weeks of the treatment period, they experienced a decrease of at least 30 percent in the mean abdominal pain score from baseline during a particular week. The Abdominal Pain score assesses the worst of a patient's abdominal pain in the past 24 hours using an 11-point scale (from 0-10), where 0 represents no abdominal pain and 10 represents very severe abdominal pain.
Abdominal Pain and Complete Spontaneous Bowel Movement (APC) Responder, 6 Out of 12 Weeks.
Time frame · Change from Baseline to Week 12
A patient is considered an APC responder if, for at least 6 of the 12 weeks of the treatment, the patient experienced an increase of at least 1 Complete Spontaneous Bowel Movement (CSBM) from baseline and experienced a decrease of at least 30 percent in their Abdominal Pain (AP)score during a particular week. The AP score assesses the worst of a patient's AP in the past 24 hours using an 11-point scale (from 0-10), where 0 represents no AP and 10 represents very severe AP. A CSBM was defined as a Spontaneous Bowel Movement (SBM) that was associated with a sense of complete evacuation.
12-Week Complete Spontaneous Bowel Movement (CSBM) Frequency Rate
Time frame · Change from Baseline to Week 12
The number of CSBMs per week.
12-Week Spontaneous Bowl Movement (SBM) Frequency Rate
Time frame · Change from Baseline to Week 12
The number of Spontaneous Bowl Movements experienced per week.
12-Week Stool Consistency
Time frame · Change from Baseline to Week 12
The consistency of each BM was assessed by patients using the 7-point Bristol Stool Form Scale (BSFS) from 1 to 7. 1. = separate hard lumps like nuts \[difficult to pass\] 2. = sausage shaped but lumpy 3. = like a sausage but with cracks on surface 4. = like a sausage or snake, smooth and soft 5. = soft blobs with clear-cut edges \[passed easily\] 6. = fluffy pieces with ragged edges, a mushy stool 7. = watery, no solid pieces \[entirely liquid\]).
12-Week Severity of Straining
Time frame · Change from Baseline to Week 12
Straining is measured on a 5-point scale where a value of 1 is "not at all" and a value of 5 is "an extreme amount.
12-Week Change in Abdominal Pain Score
Time frame · Change from Baseline to Week 12
Abdominal Pain at its worst (in the last 24 hours) is based on an 11-point scale where 0 represents no abdominal pain and 10 represents very severe abdominal pain.
12-Week Change in Abdominal Discomfort
Time frame · Change from Baseline to Week 12
Abdominal Discomfort is measured on an 11-point scale where a value of 0 is "none" and a value of 10 is "very severe."
12-Week Change in Bloating
Time frame · Change from Baseline to Week 12
Bloating was assessed on an 11-point scale where a value of 0 is "none" and a value of 10 is "very severe".
Complete Spontaneous Bowl Movement (CSBM) Responder for 6 Weeks Out of 12 Weeks of Treatment
Time frame · Change from Baseline to Week 12
A patient is considered to be a CSBM responder if, for at least 6 out of the 12 weeks of the treatment period, an increase of at least 1 CSBM per week from baseline was experienced.
Abdominal Pain Responder for 6 Out of 12 Weeks
Time frame · Change from Baseline to Week 12
A patient is considered to be an abdominal pain responder if, for at least 6 out of the 12 weeks of the treatment period, they experienced a decrease of 30 percent or more in the abdominal pain score from baseline. The Abdominal Pain score assesses the worst of a patient's abdominal pain in the past 24 hours using an 11-point scale (from 0-10), where 0 represents no abdominal pain and 10 represents very severe abdominal pain.
12-Week Percent of Abdominal Pain-free (APF) Days
Time frame · Change from Baseline to Week 12
Abdominal pain free (APF) days are those days where the patient reported a score of '0' for abdominal pain at its worst Abdominal Pain at its worst (in the last 24 hours) is based on an 11-point scale where 0 represents no abdominal pain and 10 represents very severe abdominal pain.
Eligibility
Inclusion Criteria: * Patient meets protocol criteria for IBS: reports abdominal discomfort or pain that has two or more of the following three features: 1. Relieved with defecation 2. Onset associated with a change in frequency of stool 3. Onset associated with a change in form (appearance) of stool * Patient reports \< 3 bowel movements (BMs) per week (in the absence of any laxative, suppository, or enema use during the preceding 24 hours) and reports straining, lumpy or hard stools, and/or sensation of incomplete evacuation during \> 25% of BMs * Patient has successfully completed protocol procedures (with no clinically significant findings): physical exam, 12-lead ECG, or clinical laboratory tests (some patients may require a colonoscopy per American Gastroenterological Association (AGA) guidelines) * Patient is compliant with Interactive Voice Response System (IVRS) for daily diary reporting of BM habits and IBS symptoms Exclusion Criteria: * Patient has history of loose or watery stools for \>25% of BMs * Patient has a structural abnormality of the gastrointestinal (GI) tract or a history of a disease or condition that can affect GI motility * Patient has any protocol-excluded or clinically significant medical or surgical history or concomitant medication use that could confound the study assessments
Study locations
Canada · United States. Showing up to 24 locations stored in the fast local snapshot.
Forest Investigative Site 037
Birmingham, Alabama, United States
Forest Investigative Site 036
Birmingham, Alabama, United States
Forest Investigative Site 135
Hueytown, Alabama, United States
Forest Investigative Site 014
Huntsville, Alabama, United States
Forest Investigative Site 080
Chandler, Arizona, United States
Forest Investigative Site 053
Mesa, Arizona, United States
Forest Investigative Site 078
Peoria, Arizona, United States
Forest Investigative Site 101
Phoenix, Arizona, United States
Forest Investigative Site 128
Phoenix, Arizona, United States
Forest Investigative Site 051
Scottsdale, Arizona, United States
Forest Investigative Site 136
Tucson, Arizona, United States
Forest Investigative Site 087
Tucson, Arizona, United States
Forest Investigative Site 094
Burbank, California, United States
Forest Investigative Site 026
Encinitas, California, United States
Forest Investigative Site 096
Foothill Ranch, California, United States
Forest Investigative Site 057
Los Angeles, California, United States
Forest Investigative Site 097
Mission Hills, California, United States
Forest Investigative Site 005
Orange, California, United States
Forest Investigative Site 024
Westlake Village, California, United States
Forest Investigative Site 021
Boulder, Colorado, United States
Forest Investigative Site 019
Colorado Springs, Colorado, United States
Forest Investigative Site 034
Denver, Colorado, United States
Forest Investigative Site 074
Longmont, Colorado, United States
Forest Investigative Site 010
Wheat Ridge, Colorado, United States
Publications
Related trials
Mayo Clinic · Irritable Bowel Syndrome With Constipation
Not applicable
Recruiting
65
2026-07
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · Colorectal Adenoma · Stage 0 Colorectal Cancer AJCC v8
Phase 2
Active, not recruiting
150
2026-07
AbbVie · Functional Constipation (FC) · Chronic Idiopathic Constipation (CIC)
Phase 3
Completed
123
2026-05
University of Nottingham · Cystic Fibrosis (CF)
Early Phase 1
Recruiting
26
2026-05
University of Wisconsin, Madison · Barrett Esophagus · Gastroesophageal Reflux Disease
Phase 1
Completed
43
2026-04
Texas Tech University Health Sciences Center, El Paso · Chronic Constipation · Diabete Mellitus
Phase 4
Active, not recruiting
23
2026-04
Md Mehedi Shahriar · Chronic Idiopathic Constipation · Irritable Bowel Syndrome (IBS-C)
Phase 4
Not yet recruiting
90
2026-02
University of Florida · Patients Scheduled for Colonoscopy
Phase 1 / Phase 2
Recruiting
10
2026-01
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.